View conference programme - The British Society for Rheumatology

Poster Viewing Session 2
Thursday 22 April 2004, 08:30 – 10:00
HEALTH SERVICES RESEARCH (151 – 188)
151 TRIAL EXCLUSIONS CAN DAMAGE OUR HEALTH: THE EXAMPLE OF NSAIDs.
P Dieppe 1 , C Bartlett 1 , S Morrant 2 , T MacDonald 2 , P Davey 2 . 1
MRC HSRC, University of Bristol,
Bristol, United Kingdom; 2 MEMO, University of Dundee, Dundee, United Kingdom
152 THE INFLUENCE OF RESOURCE LIMITATIONS ON THE USE OF BIOLOGIC AGENTS IN
SOUTH WEST ENGLAND.
SE Knights, H Averns. 1 Department of Rheumatology, North Bristol NHS Trust, Bristol, United
Kingdom; 2 Department of Rheumatology, North Devon District Hospital, Barnstaple, North Devon,
United Kingdom
153 COST EFFECTIVENESS OF PREVENTION OF NSAID-INDUCED GASTROINTESTINAL TOX I C I T Y.
RA Elliott 1 , L Hooper 2 , K Payne 3 , TJ Brown 2 , C Roberts 4 , D Symmons 5 . 1
School of Pharmacy,
Manchester University, Manchester, United Kingdom; 2 Cochrane Oral Health Group, University of
Manchester, Manchester, United Kingdom; 3 Health Economics at Manchester, St Mary’s Hospital,
Manchester, United Kingdom; 4 School of Epidemiology and Health Sciences, University of
Manchester, Manchester, United Kingdom; 5 ARC Epidemiology Unit, University of Manchester,
Manchester, United Kingdom
154 COX II SELECTIVE INHIBITORS VERSUS TRADITIONAL NSAIDS: ARE WE
USING THEM APPROPRIATELY?
WF Ng, A Hall, A Steuer. Rheumatology, Wexham Park Hospital, Slough, SL2 4HL, United
Kingdom
155 A SURVEY OF 1152 PATIENTS ON NSAIDS - ARE ‘NICE’ GUIDELINES BEING FOLLOWED
FOR PRESCRIBING COX-II INHIBITORS AND THE IMPLICATIONS FOR CLINICAL GOVERNANCE.
J Francis, A Samanta, FE Nichol. Department of Rheumatology, University Hospitals of Leicester
NHS Trust, Leicester Royal Infirmary, Leicester, United Kingdom
156 THE COST-EFFECTIVENESS OF ADALIMUMAB (HUMIRA ® ) IN PATIENTS WITH
RHEUMATOID ARTHRITIS: A UK ANALYSIS.
N Bansback 1 , A Brennan 1 , N Sengupta 2 , F Pang 3 . 1
School of Health and Related Research,
University of Sheffield, Sheffield, South Yorkshire, United Kingdom; 2 Center for Pharmaceutical
Appraisal & Outcomes Research, Abbott Laboratories Inc., Chicago, IL, United States; 3 Clinical
Research, Abbott Laboratories Ltd., Maidenhead, Berkshire, United Kingdom
157 A REGIONAL AUDIT OF THE USE OF COX-2 SELECTIVE NON-STEROIDAL
ANTI-INFLAMMATORY DRUGS (NSAIDS) IN RHEUMATOLOGY CLINICS IN THE WEST
MIDLANDS, ACCORDING TO NICE GUIDELINES.
AN Price-Forbes 1 , R Callaghan 2 , ME Allen 2 , IF Rowe 1 . West Midlands Rheumatology Services and
Training Committee. 1 Rheumatology, Worcestershire Royal Hospital, Worcester, United Kingdom;
2
Rheumatology, Walsgrave Hospital, Coventry, United Kingdom
158 EVALUATION OF THE COST-EFFECTIVENESS OF ETORICOXIB IN PATIENTS AT RISK
OF GI COMPLICATIONS IN THE UK.
A Moore 1 , C Phillips 2 , J Pellissier 3 , S Crespi 4 , E Hunsche 5 . 1
Pain Research, University of Oxford,
Oxford, United Kingdom; 2 School of Health Science, University of Wales, Swansea, United
Kingdom; 3 Health Economic Statistics, Merck & Co., Inc., Blue Bell, PA, United States; 4 Ernest
Mario School of Pharmacy, Rutgers University, Piscataway, NJ, United States; 5 Outcomes Research,
Merck & Co., Inc., Whitehouse Station, NJ, United States
51